In the ENTRUST-AF PCI (Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, 1506 patients were randomized to 60 mg edoxaban once daily plus a P2Y12 inhibitor for 12 months or TAT with a VKA, a P2Y12 inhibitor, and aspirin (for 1 to 12 months) [91]. Here, P2RY12 is linked to atrial fibrillation.